118 results about "Antibody production" patented technology

Disclosed are novel pharmaceutical, animal feed compositions and methods of treating non-human animals comprising at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s), or mixtures thereof, derived from non-woody plants of the genus Hesperaloe. Animal feed compositions may comprise a basal animal feed and water soluble solids extracted from Hesperaloe and comprising at least one saponin. The water soluble solids may comprise from about 5 to about 30 wt % saponin. The compositions of the present invention can be used for the treatment of non-human animals, such as poultry and more particularly for preventing and treating coccidiosis. An embodiment provides an immunological composition useful for inducing the production of antibodies to an antigen in a non-human animal comprising an antigen, preferably a coccidia, and a saponin composition extracted from Hesperaloe. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6),25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin and yuccaloiside C.

The invention is based on the deletion of 21 amino acids from the C-terminal region of the S2 subunit of SARS-CoV2-S protein and transporting the Si subunit, which is fused to S2 to the cell membranes. In this way, the presentation of the antigenic S1 subunit of SARS-CoV2-S protein in large amounts and in its natural structure in the cell membrane and its use as a whole cell or cell membrane has been determined as a new vaccination protocol for the SARS-CoV-2. Designing the S2 subunit of SARS-CoV2-S protein as a carrier, fusing any bacterial, viral, and tumor proteins with antigenic properties and transporting it to the cell membrane will be a comprehensive vaccination protocol that will cover all bacteria, viruses and even tumors.

A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

The invention discloses an African swine fever virus vaccine as well as related products and application thereof, and relates to the field of vaccines. The saRNA vaccine of the African swine fever virus provided by the invention adopts an optimized antigen sequence and a saRNA skeleton, and compared with a traditional African swine fever virus vaccine, the saRNA vaccine of the African swine fever virus has the advantages of being early in antibody production period, good in safety, simple in immune procedure, higher in antibody titer and the like.

Various methods and compositions for the activating or augmenting an immune response, and for augmenting an antibody production are presented herein. Also presented herein are methods of augmenting an immune response to a vaccine. Also presented herein are methods of preventing or delaying age-related decline in physical strength or exercise tolerance. Further presented herein are methods and compositions for improving wound healing. Yet further presented herein are methods for inhibiting growth of a tumor.

The utility model relates to the technical field of antibody production, and discloses a filtering device for antibody production, which comprises a filtering barrel component, the filter barrel assembly comprises: a barrel body; the barrel cover is clamped at the top of the barrel body; supporting legs are arranged at the bottom of the filtering barrel assembly; a feeding assembly is arranged at the top of the filter vat assembly, and a drain valve is arranged at the bottom of the filter vat assembly; a driving motor is mounted at the bottom of the filtering barrel assembly, and a filtering assembly is arranged in the filtering barrel assembly; a driving motor and a filtering assembly are arranged, the filtering assembly adopts three filtering covers to form a three-layer filtering cylinder, when an antibody stock solution is filtered, the antibody stock solution enters from the filtering cover on the innermost layer, then the driving motor drives the three-layer filtering cylinder to rotate, and the three-layer filtering cylinder sequentially filters the antibody stock solution from inside to outside; according to the filtering mode, the stock solution is filtered by utilizing centrifugal force, so that the filtering speed of the antibody stock solution can be greatly improved.

The application provides a YKL-40 monoclonal antibody and a preparation method and application thereof, and relates to the technical field of biological medicines.The monoclonal antibody 10F1 provided by the application has good titer.The heavy chain variable region and the light chain variable region of the monoclonal antibody are respectively inserted into different basic vectors, and the two kinds of recombinant vectors are mixed and then co-transfected into basic cells, so that a recombinant cell capable of expressing the monoclonal antibody 10F1 is obtained.The monoclonal antibody vector obtained by the application is easy to preserve and easy to control the quality of the antibody production process; the monoclonal antibody vector can recognize YKL-40 protein and has biological activity.The monoclonal antibody provided by the application can be used for YKL-40 antigen detection and other scientific researches, and has very good application value and very important scientific research guiding significance.

The invention provides a nano delivery system based on copper death induction and application of the nano delivery system in preparation of tumor immunotherapy drugs, according to the novel copper death induction nano drug Cu / ZIF-90 (at) DSF, 30 mol% of Cu (acac) 2 and disulfiram are loaded through a high-porosity structure of ZIF-90, and pH / ROS dual-responsiveness copper ion release is achieved. Animal experiments show that the Cu < 2 + > accumulation concentration of the nano-drug at a tumor site reaches 23.7 mu M, and efficient copper death is induced (the apoptosis rate is 41.3% vs and the control group is 9.2%). More importantly, by releasing HMGB1 and ATP, the CD8 < + > T cell infiltration in a tumor microenvironment is increased by 5.8 times, and the CD8 < + > T cell infiltration and the alphaPD-1 antibody generate a synergistic effect, so that the complete remission rate is increased from 18% to 67%. According to the technical breakthrough, a brand new solution is provided for solving the cold tumor immunotherapy drug resistance.

A high-mannose antibody-specific affinity material, a preparation method therefor and a use thereof. Provided are a lectin variant comprising (a) a histidine tag and (b) a cysteine-containing segment, added to the C-terminus of a reference lectin; a nucleic acid molecule encoding the lectin variant, and a vector and a cell containing the nucleic acid molecule; a composition and a matrix comprising the lectin variant; and a use of the lectin variant for reducing or removing a high-mannose antibody from a sample. The lectin variant has a specific affinity for high-mannose antibodies, and can effectively bind to high-mannose antibodies formed during antibody production, to remove high-mannose byproducts contained in recombinant antibodies, thereby effectively promoting and achieving required antibody purification in downstream stages of production.

The application discloses a HtsA-SLOdm fusion protein and application thereof in preparation of a group A streptococcus vaccine. The HtsA-SLOdm fusion protein is obtained by fusing and recombining a heme transport lipoprotein (HtsA) and a streptolysin protein containing a double-mutation site (SLOdm), can induce production of HtsA protein and SLOdm protein specific IgG antibodies in serum, has strong immunogenicity, can induce high-level IgG1 and IgG2a antibody titers, and the humoral immune response in inducing production of SLOdm protein specific IgG antibodies in serum is stronger than that of a single protein. In addition, the HtsA-SLOdm fusion protein can promote skin wound healing of mice, reduce bacterial content and inflammatory response at a skin infection site of the mice, accelerate wound healing, has almost no hemolytic activity, has high safety, and can be used for preparing a group A streptococcus vaccine.

The present application belongs to the technical field of polypeptide drugs, and particularly relates to a kind of small molecule polypeptide and its application in psoriasis treatment.The present application successfully designs and synthesizes a kind of small molecule polypeptide OGP6 with the effect of intervening psoriasis.By test verification, it can effectively target inhibition cGAS-STING signal pathway, intervene psoriasis inflammation start from source, avoid the existing biological preparation long-term antagonism single cytokine to cause the problem such as drug resistance antibody production, curative effect invalidation, and its still has the advantages such as small molecular weight, simple synthesis process, low cost, easy to scale production, therefore has good practical application value.

A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

The invention discloses a foot-and-mouth disease inactivated vaccine immunologic adjuvant composition. The foot-and-mouth disease inactivated vaccine immunologic adjuvant composition comprises a TLR4 agonist, a TLR9 agonist, an anionic surfactant and a cationic high-molecular polymer. The weight ratio of the TLR4 agonist to the TLR9 agonist to the cationic high-molecular polymer to the anionic surfactant is (50 to 150): (50 to 150): (800 to 1100): (1 to 5). The foot-and-mouth disease inactivated vaccine immunologic adjuvant composition provided by the invention not only can provide protective activity for foot-and-mouth disease antigens, but also has the advantages of fast antibody production and high antibody production level after animal immunization, so that animals can obtain good immune protection.

The present invention provides affinity-optimized and deimmunized human antibodies that specifically bind to CD3. The present disclosure also provides bispecific antibodies, including human antibodies optimized for T cell activation, etc. The present invention further relates to methods for generating human antibodies and their use in treating disease.

The present invention relates to the technical field of cancer treatment, and provides the use of lactyltransferase inhibitors in pancreatic cancer and its immunotherapy. The present invention uses a histone lactyltransferase inhibitor in combination with an anti-programmed death receptor-1 antibody as a composition for pancreatic cancer and its immunotherapy, which can enhance the immune system's recognition and clearance of cancer cells, effectively inhibit the growth of pancreatic cancer tumors, and prolong the survival time of pancreatic cancer patients. Histone lactyltransferase inhibitors reduce the infiltration level of tumor-associated neutrophils, increase the infiltration level of CD8-positive T cells, reverse the composition of the inhibitory immune microenvironment of pancreatic cancer, and produce a synergistic anti-tumor effect with anti-programmed death receptor-1 antibodies. It is suitable for the early, middle and late treatment of pancreatic cancer, improves the survival rate and treatment effect of pancreatic cancer patients, and significantly reduces the side effects of treatment, thereby improving the quality of life of pancreatic cancer patients.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

The invention relates to a compound red date extract with an immune regulation function as well as a preparation method and application thereof. The composite red date extract is prepared by taking red dates, astragalus membranaceus, Chinese yam, poria cocos, sea-buckthorn and medlar as raw materials through extraction, concentration and drying, and can be prepared into health-care food with an immune regulation function. Experiments prove that the compound red date extract prepared by the invention can enhance lymphopoiesis, delayed allergy, antibody generation, macrophage phagocytosis and NK cell activity, comprehensively improve the immune function and meet the health-care function requirement of enhancing immunity. The immunomodulatory activity of the compound red date extract is researched for the first time, and the compound red date extract has the advantages of being simple in production process, prominent in health-care function, small in dosage, safe to use, capable of being produced on a large scale and the like, thereby having wide application prospects in the aspect of preparing medicines and health-care foods for improving immunity.

The invention belongs to the technical field of polycyclic aromatic hydrocarbon artificial antigen synthesis, and relates to a novel synthesis method of a complete antigen for detecting polycyclic aromatic hydrocarbon (PAHs)-acenaphthene or fluorene. The hapten is successfully prepared through Friedel-Crafts acylation reaction, and the hapten is esterified and then coupled with carrier protein to prepare the complete antigen. These complete antigens have been identified. The invention provides a novel and efficient immunoassay technique for the detection of acenaphthene or fluorene, and achieves highly specific polyclonal antibody generation by immunoassay methods for optimizing antibody production in diagnostic and therapeutic applications associated with acenaphthene or fluorene exposure.

This invention provides a recombinant Staphylococcus aureus enterotoxin B nanoparticle protein vaccine, mSEB-mi3, its preparation method, and its applications. This invention utilizes a SpyTag / SpyCather protein linker system to connect the recombinant protein to the nanoparticle protein, allowing mSEB to be displayed on the surface of self-contained nanoparticles, thus obtaining the recombinant Staphylococcus aureus enterotoxin B nanoparticle protein mSEB-mi3. Both mSEB-SpyTag and SpyCather-mi3 proteins in this invention are induced to be expressed in soluble form in Escherichia coli. The mSEB-SpyTag and SpyCather-mi3 of this invention can be covalently bound via isopeptide bonds to form the mSEB-mi3 nanoparticle protein vaccine. The binding conditions are simple, and when combined with the adjuvant MF59, it can induce rapid antibody production in mice, generating a high-level immune response and exerting a protective effect. Furthermore, its antibody response rate and protective efficiency are superior to those of the monomeric protein mSEB.

The invention provides a construction and preparation method of a novel HPV fusion protein antigen and an application of the novel HPV fusion protein antigen in preparation of a polyclonal egg yolk antibody. Core antigen peptides of human papilloma virus 16 subtype and HPV 18 subtype capsid protein L1 are respectively connected in series with an Fc of immunoglobulin IgY and a tail peptide of immunoglobulin IgM for the first time; the recombinant fusion protein antigen is prepared through escherichia coli expression and an inclusion body renaturation technology, the method is beneficial for improving the stability and presentation capacity of antigen peptide, laying hens are directly immunized with the purified novel HPV fusion protein antigen, after an antibody is generated, the antibody is purified through the steps of salting out, dialysis and the like, and the antibody is obtained. Verification shows that the obtained egg yolk antibody can be combined with L1 proteins of HPV16 and HPV18, and has the capability of preventing or treating infection of HPV16 and HPV18.

An example method of training a large language model for antibody generation includes: receiving a training corpus comprising a plurality of antigen amino acid sequences and a corresponding plurality of antibody sequences, generating a plurality of training strings, where each training string comprises an antigen sequence and a corresponding antibody sequence, fine-tuning a pretrained protein language model by autoregressively training on the plurality of training strings, and outputting a fine-tuned protein language model configured to output human antibodies in response to receiving an input string comprising an antigen.

The application provides a monoclonal antibody specifically recognizing HCGP-39 and a preparation method and application thereof, and relates to the technical field of biological medicines.The application provides two monoclonal antibodies 6F6 and 6D9 of HCGP-39, and the titers are good.Based on the complementarity determining region sequences of the variable regions of the heavy chains and the light chains of the monoclonal antibodies, the variable region sequences are respectively constructed on corresponding antibody expression vectors, and the recombinant cells expressing the recombinant monoclonal antibodies can be obtained by transfecting cells.The monoclonal antibody vector obtained by the application is easy to preserve and easy to control the quality in the antibody production process; the monoclonal antibody can recognize the HCGP-39 protein, has biological activity, can be used for HCGP-39 antigen detection and the like, and has very good application value and very important scientific research guiding significance.

This invention discloses a porcine sperm-specific antibody, the coding sequence of which is shown in any one of SEQ ID No: 1-3. This invention prepares a nanobody library by immunizing alpacas with whole porcine sperm. The library can then be screened to identify antibodies that specifically bind to X or Y sperm, thus achieving X and Y sperm sorting. Furthermore, the screened antibodies are nanobodies, only 10% the size of traditional antibodies, with a simpler structure, high stability, strong specificity, and low immunogenicity. This allows for large-scale antibody expression, significantly reducing antibody production costs and facilitating industrial application.

The present disclosure relates to the generation of antibody-producing, three dimensional, immune organoids. The disclosure also provides methods useful for producing such immune organoids.

The present disclosure relates to the production of antigen binding molecules. Animals, methods, nucleic acids, and cells for producing antigen binding molecules are disclosed. Also disclosed are animals comprising a sequence that induces a suppressed immune response.

The present disclosure relates to the production of antigen binding molecules. Animals, methods, nucleic acids, and cells for producing antigen binding molecules are disclosed. Also disclosed are animals comprising a sequence for induced suppression of an immune response.

The invention relates to the technical field of anti-breast cancer tumor drugs, in particular to application of Rab001 combined with a PD-1 monoclonal antibody in preparation of anti-breast cancer tumor drugs. The invention discloses an application of Rab001 combined with a PD-1 monoclonal antibody in preparation of an anti-breast cancer tumor drug, the Rab001 promotes antigen presentation, antibody generation, formation of a tertiary lymphatic structure (TLS) and regulation of a tumor microenvironment by increasing the number and activity of peripheral circulating B lymphocytes and M1 type macrophages, M1 / M2, CD8 + T and B cells in tumors, so that the treatment effect of the PD-1 monoclonal antibody is enhanced.

The invention provides an application of a fusion protein in preparation of an SARS-CoV-2 broad-spectrum vaccine, the fusion protein comprises an NTD structural domain and an RBD structural domain of an SARS-CoV-2 spike protein, provides more conservative epitopes, can effectively stimulate the generation of a neutralizing antibody, and can effectively inhibit the generation of the SARS-CoV-2 spike protein. The vaccine prepared by using the fusion protein can provide broad-spectrum and efficient protection for the SARS-CoV-2 wild type and various mutant strains; the invention also provides an application of the broad-spectrum vaccine as an immune enhancer, and also provides an immune kit under a corresponding immune strategy, the broad-spectrum vaccine can cooperate with other existing vaccines to enhance immunity, and can independently perform a complete immune procedure, and excellent immune protection can be provided in any way.

The application belongs to the technical field of biological preparations, and particularly relates to a manganese-based hydrogel rabies vaccine and a preparation method and application thereof. The manganese-based hydrogel rabies vaccine is based on modified chitosan hydrogel, in which inactivated rabies virus and manganese ions are added. The adjuvant and antigen are co-delivered through injection, slowly dissolve with tissue effusion infiltration, gradually release manganese ions to activate cGAS-STING, enhance the activity of immune cells and stimulate the production of germinal centers. At the same time, the released antigens are processed by immune cells or immune organs to produce antibodies to block viral infection. The manganese-based hydrogel rabies vaccine can significantly improve the duration of antibody action, prolong the antibody protection time, enhance the activity of immune cells and stimulate the production of germinal centers, and improve the antibody production level.

The invention provides a recombinant glycoprotein trimer vaccine for preventing SFTS and application thereof, the vaccine comprises a recombinant Gn or Gc glycoprotein trimer, and the recombinant Gn or Gc glycoprotein trimer is composed of a Gn or Gc protein fragment and a corresponding trimer motif; the amino acid sequences of the Gn and Gc protein fragments are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2, and the motif of the trimer is T4, DMPK, MTQ, MTI, hCorla, Langerin, T3XV, MATN1 or CAT. Results show that the neutralizing antibody level induced by the Gn or Gc trimer is superior to that of a corresponding monomer or dimer, and the Gn or Gc trimer has higher cross-neutralization activity. Meanwhile, monomers and trimers of Gn or Gc can induce high-level Th1 and Th2 cytokines and antibody-dependent cytotoxic effect (ADCC) response. According to the invention, a dominant antigen structure which can more effectively stimulate the generation of the neutralizing antibody in the SFTSV is defined, and a new target spot and a new strategy are provided for enhancing immunogenicity in the research and development of the SFTSV vaccine.